Format

Send to

Choose Destination
Korean J Gastroenterol. 2018 Nov 25;72(5):245-251. doi: 10.4166/kjg.2018.72.5.245.

[Helicobacter pylori Eradication Therapy and Gastric Cancer Prevention].

[Article in Korean]

Author information

1
Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Abstract

Gastric cancer is the most common cancer in Korea and the fifth most common cancer globally. Helicobacter pylori (H. pylori) infection is considered the main etiologic agent for gastric cancer development. Most regional guidelines for H. pylori treatment recommend treating the organism to prevent gastric cancer in the high-risk group. However, evidence that such a strategy can also be applied to the general population, especially in terms of the preventive effect and safety, has not been adequately presented yet. Although a meta-analysis in the general population suggested effectiveness in decreasing gastric cancer incidence, individual studies should be critically reviewed to evaluate the soundness of the evidence. Recently published, long-term, Korean studies on metachronous gastric cancer prevention ended the controversies from previous short-term studies and confirmed the effectiveness. Currently, further prospective, large, randomized studies are ongoing in the general population and will provide more definitive, high-level evidence on this gastric cancer prevention strategy in the next decade.

KEYWORDS:

Helicobacter pylori; Stomach neoplasms

PMID:
30642140
DOI:
10.4166/kjg.2018.72.5.245
Free full text

Supplemental Content

Full text links

Icon for The Korean Society of Gastroenterology
Loading ...
Support Center